Inspiration meets innovation at Brandweek, the ultimate marketing experience. Join industry luminaries, rising talent and strategic experts in Phoenix, Arizona this September 23–26 to assess challenges, develop solutions and create new pathways for growth. Register early to save.
Drug marketer Sanofi-Synthelabo, maker of sleeping-pill brand Ambien, is reviewing its $200 million-plus global ad account, sources said last week. Agency teams from Havas, WPP and Publicis, all of which own Sanofi roster shops, are competing. Paris-based Sanofi spent about $120 million on U.S. advertising in 2002, according to Nielsen Monitor-Plus.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in